Paper II
2023 July (Supplementary) (2019 Scheme) · 100 marks · 180 min

Question

Pharmacological basis for the use of Fenofibrate in Hyperlipedemia.

Q104 marksShort Answers

Answer

Fenofibrate activates PPAR-alpha (peroxisome proliferator-activated receptor alpha) in the liver, upregulating lipoprotein lipase activity and increasing fatty acid oxidation. This markedly enhances clearance of triglyceride-rich VLDL particles from plasma, making fenofibrate the most effective drug class for lowering triglycerides specifically — the pharmacological basis for its use in hypertriglyceridemia, where statins (which act predominantly via LDL-receptor upregulation) are comparatively less effective at reducing triglyceride levels.

Other Years Asked


Revise MBBS
Preview